0032 GMT - Breathing mask maker Fisher & Paykel Healthcare adds Morgan Stanley to its bulls despite tariff headwinds in FY 2026. Fisher & Paykel Healthcare's share price eased after its annual result, which analyst David L. Bailey attributes to weaker-than-expected FY 2026 revenue and net profit guidance. Still, MS thinks growth in new apps revenue will support group-wide revenue over the medium term, with margin improvement underpinning attractive EPS growth. "While valuations are elevated, Fisher & Paykel Healthcare compares favorably relative to the sector on a number of key financial metrics," says MS, as it upgrades to the stock overweight from equal-weight. It expects Fisher & Paykel Healthcare will achieve its gross margin target of 65% in FY 2028, and its Ebit margin goal of 30% in FY 2029. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
June 01, 2025 20:32 ET (00:32 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。